TENAX THERAPEUTICS, INC.
For the period ended Dec 31, 2025. Filed Mar 10, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 10, 2026
TENX$1.69-5.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. CONSOLIDATED STATEMENTS OF CASH FLOWS
CONS OLIDATED STATEMENTS OF CASH FLOWS
(Amounts in thousands)
| 2025 · 2024 | |||
|---|---|---|---|
| CASH FLOWS FROM OPERATING ACTIVITIES | |||
| Net Loss | $(52,599) | $(17,602) | |
| Adjustments to reconcile net loss to net cash used in operating activities | |||
| Interest on debt instrument | - | 23 | |
| Stock-based compensation | 19,163 | 1,125 | |
| Changes in operating assets and liabilities | |||
| Prepaid expenses and other current assets | (4,827) | 58 | |
| Accounts payable | 2,884 | 1,062 | |
| Accrued liabilities | (421) | 523 | |
| Net cash used in operating activities | (35,800) | (14,811) | |
| CASH FLOWS FROM FINANCING ACTIVITIES | |||
| Proceeds from issuance of common stock, warrants and pre-funded warrants, net of issuance costs | 23,216 | 100,303 | |
| Proceeds from the exercise of warrants | 15,298 | 68 | |
| Payments on short-term note | - | (501) | |
| Net cash provided by financing activities | 38,514 | 99,870 | |
| Net change in cash and cash equivalents | 2,714 | 85,059 | |
| Cash and cash equivalents, beginning of period | 94,851 | 9,792 | |
| Cash and cash equivalents, end of period | $97,565 | $94,851 | |
| Supplemental Disclosures: | |||
| Cash paid for interest | $ | - | $23 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.